Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CTNM 
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: CTNM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.83
1 Year Target Price $21.83
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.43% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 346.66M USD | Price to earnings Ratio - | 1Y Target Price 21.83 |
Price to earnings Ratio - | 1Y Target Price 21.83 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 3.35 - 13.57 | Updated Date 01/7/2026 |
52 Weeks Range 3.35 - 13.57 | Updated Date 01/7/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.89% | Return on Equity (TTM) -30.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 169019881 | Price to Sales(TTM) 11.15 |
Enterprise Value 169019881 | Price to Sales(TTM) 11.15 | ||
Enterprise Value to Revenue 8.25 | Enterprise Value to EBITDA 20.76 | Shares Outstanding 30446111 | Shares Floating 16950662 |
Shares Outstanding 30446111 | Shares Floating 16950662 | ||
Percent Insiders 1.14 | Percent Institutions 58.1 |
Upturn AI SWOT
Contineum Therapeutics, Inc. Class A Common Stock
Company Overview
History and Background
Contineum Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. Founded in 2020, it emerged from the strategic acquisition of Kadmon Pharmaceuticals' fibrotic disease pipeline by Insmed Incorporated. The company is focused on advancing its lead drug candidate, CNTX-001, through clinical trials.
Core Business Areas
- Fibrotic Disease Therapeutics: Contineum Therapeutics focuses on developing small molecule inhibitors that target key pathways involved in fibrosis. Their primary goal is to address unmet medical needs in a range of fibrotic conditions.
Leadership and Structure
Contineum Therapeutics, Inc. is a privately held company. Specific details on its leadership team and organizational structure are not publicly disclosed as it operates under the umbrella of Insmed Incorporated.
Top Products and Market Share
Key Offerings
- Competitors: Key competitors in the fibrotic disease space include companies developing therapies for specific fibrotic conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and non-alcoholic steatohepatitis (NASH). Examples include Boehringer Ingelheim (OFEV), Genentech/Roche (Actelion portfolio), and Gilead Sciences.
- Description: CNTX-001 is a novel, selective, oral small molecule inhibitor of succinate dehydrogenase (SDH) intended for the treatment of fibrotic diseases. It is currently in clinical development.
- Market Share: As a pre-commercial, clinical-stage asset, market share data is not applicable.
- Product Name: CNTX-001
Market Dynamics
Industry Overview
The fibrotic disease market is characterized by a significant unmet medical need, as many fibrotic conditions currently lack effective disease-modifying treatments. The industry is focused on identifying novel targets and developing small molecules and biologics to halt or reverse fibrosis. The market is expected to grow due to increasing prevalence and a greater understanding of fibrotic pathways.
Positioning
Contineum Therapeutics is positioned as a clinical-stage biopharmaceutical company aiming to develop first-in-class or best-in-class therapies for fibrotic diseases. Its focus on a specific molecular target (SDH) provides a clear strategic direction.
Total Addressable Market (TAM)
The total addressable market for fibrotic diseases is substantial, with estimates varying by specific indication. For instance, the global idiopathic pulmonary fibrosis market alone is projected to reach billions of dollars. Contineum Therapeutics, by targeting multiple fibrotic diseases, aims to capture a significant portion of this broad TAM.
Upturn SWOT Analysis
Strengths
- Focus on a well-defined scientific pathway (SDH inhibition) for fibrotic diseases.
- Clinical-stage drug candidate (CNTX-001) with potential to address significant unmet needs.
- Backed by the resources and expertise of Insmed Incorporated.
Weaknesses
- As a clinical-stage company, it has no approved products and thus no revenue.
- High risk associated with drug development, with potential for trial failures.
- Dependence on successful clinical trial outcomes and regulatory approvals.
Opportunities
- Significant unmet need in various fibrotic diseases presents a large market opportunity.
- Advancements in understanding fibrotic mechanisms could lead to new therapeutic targets.
- Potential for partnerships or collaborations to accelerate development and commercialization.
Threats
- Competition from other companies developing therapies for fibrotic diseases.
- Challenges in clinical trial design and execution.
- Regulatory hurdles and the lengthy approval process.
- Potential for unexpected side effects or lack of efficacy in clinical trials.
Competitors and Market Share
Key Competitors
- Boehringer Ingelheim (OFEV)
- Genentech/Roche (Actelion portfolio)
- Gilead Sciences (various pipeline candidates)
Competitive Landscape
Contineum Therapeutics faces competition from established pharmaceutical companies with existing treatments or advanced pipelines in fibrotic diseases. Its competitive advantage lies in its targeted approach to SDH inhibition, which could offer a differentiated mechanism of action and potentially improved efficacy or safety profiles.
Growth Trajectory and Initiatives
Historical Growth: Contineum Therapeutics is in its early stages, with growth primarily defined by its progression through the clinical development pipeline.
Future Projections: Future projections are contingent on the successful advancement of CNTX-001 through Phase 2 and Phase 3 clinical trials and subsequent regulatory approval. Success in these stages would indicate significant future growth potential.
Recent Initiatives: The primary recent initiative for Contineum Therapeutics has been the progression of its lead candidate, CNTX-001, into clinical development.
Summary
Contineum Therapeutics is a promising clinical-stage biotechnology company focused on fibrotic diseases. Its strength lies in its targeted therapeutic approach and the potential of its lead candidate, CNTX-001. However, it faces the inherent risks of drug development and competition in a significant market. Continued success in clinical trials and regulatory approvals will be crucial for its future growth and impact.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and SEC filings (via Insmed Incorporated)
- Industry analysis reports
- Biotechnology news outlets
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and general industry knowledge. Specific financial data for Contineum Therapeutics, Inc. as a standalone entity is limited due to its private status under Insmed Incorporated. Market share data is illustrative and based on general industry understanding.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Contineum Therapeutics, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-04-05 | President, CEO & Director Mr. Carmine N. Stengone MBA, MS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.contineum-tx.com |
Full time employees 41 | Website https://www.contineum-tx.com | ||
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.